

## Satsuma Pharmaceuticals Announces Poster Presentations at the International Headache Congress

SOUTH SAN FRANCISCO, Calif., Sept. 3, 2019 /PRNewswire/ -- Satsuma Pharmaceuticals, Inc. ("Satsuma" or "the Company"), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder) for the acute treatment of migraine, today announced that it will be presenting two posters at the 19<sup>th</sup> Congress of the International Headache Society convening at the Convention Centre Dublin (CCD) in Dublin, Ireland from the 5<sup>th</sup> to the 8<sup>th</sup> of September 2019.

<b>Title:</b>	<b>Comparison of the Pharmacokinetics of STS101, an Intranasal Dry Powder Formulation of Dihydroergotamine, with Other Intranasal, Injectable, and Oral Inhaled DHE Formulations</b>
<b>Presenter:</b>	Shannon Strom, Ph.D., Satsuma Pharmaceuticals, Inc.
<b>Poster:</b>	IHC-PO-362

<b>Title:</b>	<b>STS101 (Dry Powder Intranasal Dihydroergotamine) Drug-Device Combination Achieves Consistent and Robust Delivery Performance for Migraine Patients</b>
<b>Presenter:</b>	Robert Schultz, Satsuma Pharmaceuticals, Inc.
<b>Poster:</b>	IHC-PO-363

The posters will be on display from 9:00 a.m. IST on Saturday, September 7 through 10:15 a.m. IST on Sunday, September 8 with lead authors Shannon Strom, Ph.D. and Robert Schultz in attendance from 2:45-3:45 p.m. IST on Saturday, September 7. Copies of the posters will also be available for download on the Publications section of Satsuma's website: <https://www.satsumarx.com/publications/>

For further information regarding the STS101 Phase 3 EMERGE efficacy trial, see [www.ClinicalTrials.gov](http://www.ClinicalTrials.gov), identifier NCT03901482: [A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of Migraine](#) (EMERGE).

### About Satsuma Pharmaceuticals and STS101

Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic product for the acute treatment of migraine, STS101. STS101 is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate (DHE), which can be quickly and easily self-administered with a proprietary pre-filled, single-use, nasal delivery device. In developing STS101, Satsuma has applied proprietary nasal drug delivery, dry-powder formulation, and engineered drug particle technologies to create a compact, simple-to-use, non-injectable DHE product that can be rapidly self-administered in a matter of seconds. The Company believes STS101 could, if approved, potentially be an attractive migraine treatment option for many patients and may enable a larger number of people with migraine to realize the long-recognized therapeutic benefits of DHE therapy. STS101 has undergone extensive pre-clinical development, recently completed a Phase 1 clinical trial, and is currently in Phase 3 development.

Satsuma is headquartered in South San Francisco, California with operations in both California and Research Triangle Park, North Carolina.

### **CORPORATE CONTACTS:**

Tom O'Neil, Chief Financial Officer  
Satsuma Pharmaceuticals, Inc.  
[tom@satsumarx.com](mailto:tom@satsumarx.com)

John Kollins, President and Chief Executive Officer  
Satsuma Pharmaceuticals, Inc.  
[john@satsumarx.com](mailto:john@satsumarx.com)

